fed central bank digital currency Top

In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.In July this year, when Shanghai promoted the establishment of the parent fund of three leading industries with a total scale of 100 billion yuan, it said that it would focus on the three leading industries of integrated circuits, biomedicine and artificial intelligence, and give play to the functions of "investing early and investing small", industrial investment, merger and acquisition integration, and strengthening the chain, so as to improve the overall energy level and development level of the three leading industries in Shanghai.

The "10 billion yuan M&A fund for integrated circuit design industry" stated in the Action Plan is considered by the market as a supplement to the 100 billion yuan parent fund for the three leading industries.Since the second half of 2024, there have been frequent large-scale acquisitions in the A-share market, and the biomedical industry has accelerated its integration. For example, China Bio-Pharmaceutical intends to acquire about 55% equity of Haooubo by means of "agreement+offer", Qianhong Pharmaceutical plans to invest 390 million yuan for bankruptcy and reorganization of Fiona Fang Pharmaceutical, Pharmacists help to acquire a piece of medicine, Xinnuowei plans to acquire 100 grams of Shiyao, and Sichuan Shuangma announced the cross-border acquisition of Jianyuan Medicine ...Bu Rixin believes that in the past few years, after the IPO tide of semiconductors, especially chip design companies, the IPO dividend period of chip design companies has basically ended. "Except for some large chip fields that have not been completely replaced, there are listed companies in other sub-fields, and these fields have already experienced serious involution at the level of low-end products. In the follow-up, if enterprises in these fields are encouraged to conduct IPOs, it is equivalent to encouraging disorderly competition in the industry. "

Since the second half of 2024, there have been frequent large-scale acquisitions in the A-share market, and the biomedical industry has accelerated its integration. For example, China Bio-Pharmaceutical intends to acquire about 55% equity of Haooubo by means of "agreement+offer", Qianhong Pharmaceutical plans to invest 390 million yuan for bankruptcy and reorganization of Fiona Fang Pharmaceutical, Pharmacists help to acquire a piece of medicine, Xinnuowei plans to acquire 100 grams of Shiyao, and Sichuan Shuangma announced the cross-border acquisition of Jianyuan Medicine ...However, in the field of large chips such as GPU, it has not yet run out of listed companies. It can be seen that Moore Thread, Biwa Technology, Suiyuan Technology, etc. have started the listing counseling process one after another.Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.